Ana M Cruz

Dr. Ana M Cruz

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2017 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
JWJulia M. Vlachaki Walker
Julia M. Vlachaki Walker
JRJosephine L. Robb
Josephine L. Robb
ACAna M Cruz
Ana M Cruz
AMAmrinder Malhi
Amrinder Malhi
PPPaul Weightman Potter
Paul Weightman Potter
CBCraig Beall
Craig Beall
Aim: To test the hypothesis that, given the role of AMP ‐activated protein kinase ( AMPK ) in regulating intracellular ATP levels, AMPK may alter ATP release from astrocytes, the main sources of extracellular ATP ( eATP ) within the brain. Materials and Methods: Measurements of ATP release were made from human U373 astrocytoma cells, primary mouse hypothalamic ( HTAS ) and cortical astrocytes ( CRTAS ) and wild‐type and AMPK α1/α2 null mouse embryonic fibroblasts ( MEFs ). Cells were treated with drugs known to modulate AMPK activity: A ‐769662, AICAR and metformin, for up to 3 hours. Intracellular calcium was measured using F luo4 and F ura‐2 calcium‐sensitive fluorescent dyes. Results: In U373 cells, A ‐769662 (100 μM) increased AMPK phosphorylation, whereas AICAR and metformin (1 mM) induced a modest increase or had no effect, respectively. Only A ‐769662 increased eATP levels, and this was partially blocked by AMPK inhibitor C ompound C . A‐769662‐induced increases in eATP were preserved in AMPK α1/α2 null MEF cells. A‐769662 increased intracellular calcium in U373 , HTAS and CRTAS cells and chelation of intracellular calcium using BAPTA‐AM reduced A ‐769662‐induced eATP levels. A‐769662 also increased ATP release from a number of other central and peripheral endocrine cell types. Conclusions: AMPK is required to maintain basal eATP levels but is not required for A ‐769662‐induced increases in eATP . A‐769662 (>50 μM) enhanced intracellular calcium levels leading to ATP release in an AMPK and purinergic receptor independent pathway.

14 October 2019 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
MDMarlou L Dirks
Marlou L Dirks
BWBenjamin T Wall
Benjamin T Wall
BOBritt Otten
Britt Otten
ACAna M Cruz
Ana M Cruz
MDMandy V Dunlop
Mandy V Dunlop
FSFrancis B Stephens
Francis B Stephens
Context Physical inactivity and high-fat overfeeding have been shown to independently induce insulin resistance. Objective Establish the contribution of muscle disuse and lipid availability to the development of inactivity-induced insulin resistance. Design, setting, participants, and interventions: Twenty healthy males underwent seven days of forearm cast immobilization combined with a fully-controlled eucaloric (CON, n=10, age 23±2 yr, BMI 23.8±1.0 kg·m-2) or high-fat diet providing 50% excess energy from fat (HFD, n=10, age 23±2 yr, BMI 22.4±0.8 kg·m-2). Main outcome measures Prior to casting, and following 2 and 7 days of immobilization, forearm glucose uptake (FGU) and non-esterified fatty acid (NEFA) balance were assessed using the arterialized venous-deep venous (AV-V) forearm balance method following ingestion of a mixed macronutrient drink. Results Seven days of HFD increased body weight by 0.9±0.2 kg (P=0.002), but did not alter fasting, arterialized whole-blood glucose and serum insulin concentrations or the associated HOMA-IR or Matsuda indices. Two and seven days of forearm immobilization led to a 40±7% and 52±7% decrease in FGU, respectively (P<0.001), with no difference between day 2 and 7 and no effect of HFD. Forearm NEFA balance tended to increase following two and seven days of immobilization (P=0.095). Conclusions forearm immobilization leads to a rapid and substantial decrease in FGU, which is accompanied by an increase in forearm NEFA balance but is not exacerbated by excess dietary fat intake. Altogether, our data suggest that disuse-induced insulin resistance of glucose metabolism is occurs as a physiological adaptation in response to the removal of muscle contraction.

18 April 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
BWBenjamin Wall
Benjamin Wall
ACAna M Cruz
Ana M Cruz
BOBritt Otten
Britt Otten
MDMandy V Dunlop
Mandy V Dunlop
JFJonathan Fulford
Jonathan Fulford
MDMarlou L Dirks
Marlou L Dirks
Context Anabolic resistance is mechanistically implicated in muscle disuse atrophy. Objective Assess whether anabolic resistance is associated with reduced postprandial amino acid uptake or exacerbated by excess lipid availability. Design, setting, participants and interventions Twenty men underwent 7 days of forearm immobilization while consuming a eucaloric (CON; n=11) or high-fat overfeeding (HFD; n=9; 50% excess energy as fat) diet (parallel design) within our Nutritional Physiology Research Unit. Main outcome measures Pre- and post- immobilization we measured forearm muscle cross sectional area (aCSA), and postabsorptive and postprandial (3 h post ingestion of a liquid, protein rich, mixed meal) forearm amino acid metabolism using the arterialised venous-deep venous balance method and infusions of L-[ring-2H5]phenylalanine and L-[1-13C]leucine. Results Immobilization did not affect forearm muscle aCSA in either group, but tended to reduce postabsorptive phenylalanine (P=0.07) and leucine (P=0.05) net balances equivalently in CON and HFD. Mixed meal ingestion switched phenylalanine and leucine net balances from negative to positive (P<0.05), an effect blunted by immobilization (P<0.05) and to a greater extent in HFD than CON (P<0.05). Pre-immobilization, meal ingestion increased leucine rates of disappearance (Rd; P0.05). Conclusions Disuse impairs the ability of a protein-rich meal to promote positive muscle amino acid balance, which is aggravated by dietary lipid oversupply. Moreover, disuse reduced postprandial forearm amino acid uptake; however, this is not worsened under high-fat conditions.

29 August 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAna M Cruz
Ana M Cruz
YMYasaman Malekizadeh
Yasaman Malekizadeh
JWJulia M. Vlachaki Walker
Julia M. Vlachaki Walker
PPPaul Weightman Potter
Paul Weightman Potter
KPKatherine Pye
Katherine Pye
CBCraig Beall
Craig Beall
AMP-activated protein kinase (AMPK) is a critical cellular and whole body energy sensor activated by energy stress, including hypoglycemia, which is frequently experienced by people with diabetes. Previous studies using direct delivery of an AMPK activator to the ventromedial hypothalamus (VMH) in rodents increased hepatic glucose production. Moreover, recurrent glucoprivation in the hypothalamus leads to blunted AMPK activation and defective hormonal responses to subsequent hypoglycemia. These data suggest that amplifying AMPK activation may prevent or reduce frequency hypoglycemia in diabetes. We used a novel brain-permeable AMPK activator, R481, which potently increased AMPK phosphorylation in vitro . R481 significantly increased peak glucose levels during glucose tolerance tests in rats, which were attenuated by treatment with AMPK inhibitor SBI-0206965 and completely abolished by blockade of the autonomic nervous system. This occurred without altering insulin sensitivity measured by hyperinsulinemic-euglycemic clamps. Endogenous insulin secretion was not altered by R481 treatment. During hyperinsulinemic-hypoglycemic clamp studies, R481 treatment reduced exogenous glucose requirements and amplified peak glucagon levels during hypoglycemia. These data demonstrate that peripheral administration of the brain permeable AMPK activator R481 amplifies the counterregulatory response to hypoglycemia in rats, which could have clinical relevance for prevention of hypoglycemia.

22 December 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
EPEmily Jane Parkes
Emily Jane Parkes
ACAna M Cruz
Ana M Cruz
AKAmanpreet Kaur
Amanpreet Kaur
GCGeorgina Rose Clark
Georgina Rose Clark
TPThomas E. Pulford
Thomas E. Pulford
DLDavid Sidney Leake
David Sidney Leake
LDL can be oxidised in the lysosomes of macrophages. Cysteamine, a thiol antioxidant that accumulates in lysosomes, inhibits the oxidation of LDL by iron at lysosomal pH (pH 4.5) and protects against atherosclerosis in mice. We have investigated the effects of cysteamine and its related thiol cysteine and their disulfides on LDL oxidation by iron or copper at both pH 4.5 and 7.4. The oxidation of LDL by ferrous iron (5 µM) at pH 4.5 was delayed 12.9-fold by 100 µM cysteamine and 5.6-fold by 100 µM cysteine. Cystamine and cystine (the disulfide oxidation products of cyteamine and cysteine, respectively) did not inhibit LDL oxidation by ferrous iron at pH 4.5. LDL oxidation by 5 µM copper at pH 4.5 was delayed about 2-fold by 100 µM of the thiols cysteamine and cysteine, but there was little effect of the disulfides cystamine and cystine. Cysteamine and cystine did not inhibit the oxidation of LDL by ferrous iron at pH 7.4 in a MOPS buffer and even accelerated LDL oxidation later in the incubation. Cysteine initially inhibited the oxidation of LDL by ferrous iron at pH 7.4, but increased it later. LDL oxidation by copper at pH 7.4 was delayed 7.8-fold by 100 µM cysteamine. Cysteine delayed LDL oxidation by copper at pH 7.4 to a similar extent as cysteamine but, unlike cysteamine, continued to decrease the rate of oxidation even after the period of total inhibition had ended. Cystamine had no effect on LDL oxidation by copper at pH 7.4, but cystine partially inhibited LDL oxidation. The effects of thiols and disulfides on LDL oxidation, therefore, depend not only on the metal ion catalysing the oxidation but also on the pH of the environment.